You are here

  • Home
  • Archive
  • Volume 82, Issue 2
  • Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF
Rheumatoid arthritis
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

 

Online download statistics by month:

Online download statistics by month: October 2022 to April 2025

AbstractFullPdf
Oct 202210753958556
Nov 20223922375248
Dec 20221430160115
Jan 20232435258165
Feb 20231832243178
Mar 20231758186170
Apr 2023110012296
May 20238359482
Jun 20237718377
Jul 20236739577
Aug 20235585846
Sep 2023889125109
Oct 20231114103100
Nov 20236918878
Dec 20235085744
Jan 20245178156
Feb 20247667531
Mar 20246026049
Apr 20244144641
May 20241230114107
Jun 20242148167153
Jul 20248164641
Aug 20244192914
Sep 20246564839
Oct 20245034320
Nov 20243814428
Dec 20243743317
Jan 20253213814
Feb 20251301410
Mar 202521103
Apr 202516125
Total3858338652769